David A. Shoultz, MBA, PhD, MS, BSN
Affiliate Assistant Professor, Epidemiology (primary department)
Affiliate Assistant Professor, Global Health
Deputy Director, Global Health, Infectious Disease Development
I am interested in global health product discovery, development, and delivery. I am also interested in innovative finance for global health product development. I am eager to collaborate with other faculty members and am available to work with master’s and doctoral students who share my interests and commitment to global health product development.
Dr. David Shoultz is the Global Program Leader for Drug Development at PATH. PATH is an international organization that drives transformative innovation to save lives and improve health, especially among women and children. PATH works across five platforms – vaccines, drugs, diagnostics, devices, and system & service innovations. PATH works with countries and other partners around the world to bring innovation to scale. PATH’s Drug Development program is working to discover, develop, and deliver safe, effective, and affordable new treatments for diseases disproportionately affecting people in developing countries.
Prior joining PATH in November 2014, David was the director of grantee & partner engagement at the Bill & Melinda Gates Foundation and a member of the foundation’s leadership team. Having joined the Gates Foundation in 2009, David held several different roles at the foundation, including deputy director in the Global Health Program. He was also the relationship manager for PATH, and served as board member at OneWorld Health, the predecessor to the PATH Drug Development program.
Dr. Shoultz received his bachelor’s degree, MS, and Ph.D from the University of Washington in Seattle. His MBA is from the Albers School of Business & Economics at Seattle University, where he is a faculty member in the Executive MBA Program. For the past 14 years, he has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington.
Prior to joining the foundation, Dr. Shoultz worked as a member of the senior management team for a number of clinical research organizations, participating in the development of new medicines, including PPD, PRA International, and Biomedical Systems.
In addition to his role at the Gates Foundation, Dr. Shoultz is on the Board of the Geneva Foundation, where he also serves as the inaugural chair of the Scientific Advisory Committee. Follow him on Twitter @shoultztweets.
Bill and Melinda Gates Foundation
Global Health, Infectious Disease Development
PO Box 23350
Seattle, WA 98102
Global health product development. New medicine development. Research & development. Innovative financing for global health R&D.
Other Areas of Involvement
Member, Board of Directors and Inaugural Chair of the Scientific Advisory Board, the Geneva Foundation - a private, non-profit organization created in 1993 with the sole purpose to support and promote the advancement of military medicine. www.genevausa.org
MBA, Seattle University, Albers School of Business & Economics, 2012
PhD, Epidemiology, University of Washington 1997
MS, Epidemiology, University of Washington 1995
BSN, University of Washington, School of Nursing 1991
Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemo. 2003 51: 1261-1268.
Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):340-5.
Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000 Dec;36(7):2056-63.
Cannon, CP, Gibson CM, Lambrew CT, Shoultz DA, et al. Relationship of symptom-onset-to-balloon-time and door-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000 Jun 14; 283(22):2941-7.
Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every NR. Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Investigators in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2000 Feb;35(2):371-9.
Bratton, S.L., D.A. Shoultz, M.A. Williams. 1996. Recurrent risk of low birth weight deliveries among women with a prior very low birth weight delivery. Am J Perinatol 13:147-50.
Shoultz, D.A., L.A. Koutsky, D.A. Galloway. 1996. Epidemiology and Modes and Transmission. Book Chapter In: Human Papillamavirus Infections in Dermatovenereology (Gross, G., G. vonKrogh, Eds.)
Safer, Faster, Cheaper: Improving Clinical Trials and Regulatory Pathways to Fight Neglected Diseases – a report from the Center for Global Development working group on improving clinical trials and regulatory pathways (Thomas Bollyky, Chair), Center for Global Development, Washington, D.C., October 31, 2011.
Financing and partnerships for global health challenges. A blog on Impatient Optimists, December 16, 2011. http://www.impatientoptimists.org/Posts/2011/12/Show-Me-the-Money-Developing-Products-for-Our-Biggest-Global-Health-Challenges
Strong relationships with grantees: working with the Gates Foundation. A blog on Impatient Optimists, June 12, 2013.
Last Reviewed on 12/9/2014